Seroplasma Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 07-01-2025
- Paid Up Capital ₹ 0.10 M
as on 07-01-2025
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.09 Cr
as on 07-01-2025
- Revenue 6598.90%
(FY 2021)
- Profit 1500.39%
(FY 2021)
- Ebitda 7503.36%
(FY 2021)
- Net Worth 191.23%
(FY 2021)
- Total Assets 35.03%
(FY 2021)
About Seroplasma Biotech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹2.09 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rabinder Chadha and Parmanand Bhatia serve as directors at the Company.
- CIN/LLPIN
U85191MH2012PTC235383
- Company No.
235383
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Seroplasma Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rabinder Chadha  | Director | 06-Sep-2012 | Current |
| Parmanand Bhatia | Director | 06-Sep-2012 | Current |
Financial Performance of Seroplasma Biotech.
Seroplasma Biotech Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 6598.9% increase. The company also saw a substantial improvement in profitability, with a 1500.39% increase in profit. The company's net worth Soared by an impressive increase of 191.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Seroplasma Biotech?
In 2021, Seroplasma Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lab-Care Diagnostics (India) Private LimitedActive 25 years 9 monthsRabinder Chadha is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Apr 2016 | ₹7.56 M | Satisfied |
The Shamrao Vithal Co Operative Bank Limited Creation Date: 14 Mar 2013 | ₹1.34 Cr | Satisfied |
How Many Employees Work at Seroplasma Biotech?
Unlock and access historical data on people associated with Seroplasma Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Seroplasma Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Seroplasma Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
